Profile of Silodosin

European Urology, Supplements

Volumn 9, Issue 4, 2010, Pages 491-495

  Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

1A adrenoceptor antagonist; Efficacy; Pharmacology; Safety; Silodosin; Tamsulosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DIURETIC AGENT; KETOCONAZOLE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLOPPY IRIS SYNDROME; HUMAN; HYPERTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; IRIS DISEASE; LOWER URINARY TRACT SYMPTOM; MAXIMUM PLASMA CONCENTRATION; NOCTURIA; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; SCORING SYSTEM; SYMPTOM; URINARY FREQUENCY;

EID: 77952744200     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.04.001     Document Type: Article

References (20)

1. Unpubl. data, Recordati SpA, Milano, Italy. Summary of Safety (September 2008), Common Technical Documents on file, Recordati, Milano, Italy.
2. Michel M.C., and Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147 (2006) S88-119
3. Roehrborn C.G. Efficacy of α-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 11 Suppl 1 (2009) S1-8
4. Guimaraes S., and Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 53 (2001) 319-356
5. Tatemichi S., Kiguchi S., Kobayashi M., Yamazaki Y., Shibata N., and Uruno T. Cardiovascular effects of the selective alpha1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung 56 (2006) 682-687
6. Morganroth J., Lepor H., Hill L.A., Volinn W., and Hoel G. Effects of the selective alpha(1A)-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clin Pharmacol Ther 87 (2010) 609-613
7. Yoshida M., Homma Y., Kawabe K., and Silodosin. a novel selective α1A adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Exp Opin Invest Drugs 16 (2007) 1955-1965
8. EPARs for authorised medicinal products for human use: Urorec. European Medicines Agency Web site. http://www.ema.europa.eu/humandocs/Humans/EPAR/urorec/urorec.htm.
9. Guay D.R.P. Silodosin: an orally active selective α1-adrenoceptor antagonist for benign prostatic hyperplasia. Aging Health 5 (2009) 459-473
10. Matsubara Y., Kanazawa T., Kojima Y., et al. Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi 126 (2006) 237-245
11. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
12. Macdiarmid S.A., Hill L.A., Volinn W., and Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1A-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 75 (2010) 520-525
13. Marks L., Gittelmann M.C., Hill L.A., Volinn W., and Hoel G. Rapid efficacy of the highly selective alpha 1A-adrenoceptor antagonists silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181 (2009) 2634-2640
14. Chapple C. Eur Urol. In press.
15. Marks L., Gittelmann M.C., Hill L.A., Volinn W., and Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 74 (2009) 1318-1324
16. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
17. Michel M.C. α1-adrenoceptors and ejaculatory function. Br J Pharmacol 152 (2007) 289-290
18. Kobayashi K., Masumori N., Hisasue S., et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med 5 (2008) 2185-2190
19. Kobayashi K., Masumori N., Kato R., et al. Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration. Int J Impot Res 21 (2009) 306-310
20. Avisar R., and Weinberger D. Intraoperative floppy iris syndrome: possible relationship with alpha-1 adrenergic receptor antagonists. IMAJ 11 (2009) 42-44